Assertio (ASRT) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Assertio Reports Third Quarter 2025 Financial Results Advanced Integration Ef orts to Consolidate Subsidiaries and Pulled Forward Two Quarters of Rolvedon Demand Promotes Paul Schwichtenberg to President and COO Narrows FY2025 Net Product Sales Guidance Range to $110 to $112 Million and Adjusted EBITDA Range to $14 to $16 Million LAKE FOREST, IL. – November 10, 2025 – Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial cap ...